Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Duquette M, Sadow PM, Husain A, Sims JN, Antonello ZA, Fischer AH, Song C, Castellanos-Rizaldos E, Makrigiorgos GM, Kurebayashi J, Nose V, Van Hummelen P, Bronson RT, Vinco M, Giordano TJ, Dias-Santagata D, Pandolfi PP, Nucera C.
Duquette M, et al. Among authors: kurebayashi j.
Oncotarget. 2015 Dec 15;6(40):42445-67. doi: 10.18632/oncotarget.6442.
Oncotarget. 2015.
PMID: 26636651
Free PMC article.